All research
2026-07-02 PubMed

PGC-1alpha/Nrf2 signaling imbalance drives doxorubicin cardiotoxicity, restored by combined activation

PGC-1α-Nrf2 Signaling Imbalance Mediates Doxorubicin-Induced Mitochondrial Dysfunction and Cardiac Injury.

Background

Doxorubicin (DOX) is a potent chemotherapeutic, but its use is limited by severe cardiotoxicity, primarily driven by mitochondrial dysfunction and excessive oxidative stress. Current strategies often fall short in preventing this damage. While PGC-1alpha is crucial for mitochondrial biogenesis and function, and Nrf2 orchestrates antioxidant defenses, the precise interplay and functional coupling between these pathways in DOX-induced cardiac injury have remained unclear, representing a critical gap in therapeutic understanding.

Study Design

Researchers employed transcriptomic analysis, human iPSC-derived cardiomyocytes, and doxorubicin (DOX)-induced murine models to dissect the functional interaction between peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and nuclear factor erythroid 2-related factor 2 (Nrf2). They used pharmacological activation and gene knockdown techniques to manipulate these pathways. The study investigated DOX's impact on mitochondrial metabolism and antioxidant responses, evaluating endpoints like mitochondrial respiration, oxidative stress markers, and cardiac structure/function through histological approaches and other assays.

Results

DOX exposure significantly suppressed oxidative phosphorylation (OXPHOS), tricarboxylic acid cycle (TCA cycle), and mitochondrial biogenesis pathways, while concurrently activating Nrf2-mediated antioxidant responses, indicating a functional uncoupling. Activation of PGC-1alpha alone restored mitochondrial respiration and reduced oxidative stress. Conversely, PGC-1alpha deficiency severely aggravated mitochondrial collapse. Notably, Nrf2-mediated antioxidant protection was significantly attenuated under PGC-1alpha deficiency, demonstrating its dependence on mitochondrial integrity.

In vivo, combined activation of PGC-1alpha and Nrf2 more effectively improved mitochondrial function, reduced oxidative injury, and preserved cardiac structure and function compared with single interventions.

Key Findings

  • Doxorubicin (DOX) uncouples mitochondrial metabolic regulation (PGC-1alpha) from antioxidant defense (Nrf2).
  • PGC-1alpha activation restored mitochondrial respiration and reduced oxidative stress in DOX-treated cells.
  • PGC-1alpha deficiency aggravated mitochondrial collapse and attenuated Nrf2's antioxidant protection.
  • Combined activation of PGC-1alpha and Nrf2 synergistically improved mitochondrial function and cardiac health in vivo.

Why It Matters

These findings highlight that doxorubicin cardiotoxicity is not just about oxidative stress or mitochondrial damage, but a critical imbalance between them. Targeting the PGC-1alpha/Nrf2 axis represents a promising therapeutic strategy to prevent or mitigate DOX-induced cardiac injury. This suggests that future clinical protocols for DOX chemotherapy could incorporate adjunctive therapies designed to simultaneously bolster mitochondrial health and antioxidant capacity, potentially allowing for safer and more effective cancer treatment. It shifts the focus from single-pathway interventions to a more integrated approach for cardioprotection.


doxorubicin cardiotoxicity mitochondrial-dysfunction oxidative-stress pgc-1alpha nrf2
Source: pubmed:42387999 · Ingested 2026-07-02 · Digest: gemini-2.5-flash